104615-18-1Relevant articles and documents
ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS
-
, (2020/06/05)
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of FOXA1 and/or FOXA1 gene targets, such as certain breast, liver and/or prostate cancers, including luminal and/or ER-positive forms of breast cancer. Three previously identified adenosine receptor antagonists, CGS-15943, MRS-1220 and SCH-58261, as well as furan ring moiety-possessing derivatives of CGS-15943 are specifically provided for killing cancer cells in a manner that appears to involve activation of the aryl hydrocarbon receptor (AHR) by such compounds. The instant disclosure therefore provides for selecting and/or administering CGS-15943, MRS-1220, SCH-58261 and/or a furan-possessing derivative of CGS-15943, MRS-1220 and/or SCH-58261 as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided
Synthesis of Triazoloquinazoline and Triazolo-1,4-benzodiazepine Derivatives
Gatta, Franco,Giudice, Del, Maria Rosaria,Borioni, Maria
, p. 11 - 16 (2007/10/02)
Some triazoloquinazolin-5(6H)-ones 7, the corresponding isomers triazoloquinazolin-5(6H)-ones and the 5-amino derivatives 8,9 and 11 have been synthesized starting from the acylamidrazones 5.The preparation of 5H-triazol
Structure-Activity Profile of a Series of Novel Triazoloquinazoline Adenosine Antagonists
Francis, John E.,Cash, William D.,Psychoyos, Stacy,Ghai, Geetha,Wenk, Paul,et al.
, p. 1014 - 1020 (2007/10/02)
During a search for benzodiazepine receptor modulators, a highly potent adenosine antagonist (CGS 15943) was discovered.The compound was defined as resonance-stabilized hybrid of the canonical structures 9-chloro-2-(2-furyl)triazoloquinazoli